Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6001737 | 0.80 | HRH4 (0.51) | TSHRCYP1A2CYP2A6ALDH1A1KMT2A | |
| SCHEMBL21047741 | 0.80 | NPEPPS (0.41) | CYP1A2MAPTALDH1A1KMT2A | |
| SCHEMBL6997562 | 0.79 | CYP1A2 (0.56) | TSHRCYP1A2CYP2A6ALDH1A1LMNA | |
| SCHEMBL7562950 | 0.73 | HTR1A (0.61) | TSHRCYP1A2MAPTALDH1A1LMNA | |
| SCHEMBL28883489 | 0.72 | HCAR1 (0.41) | HCAR1TSHRCYP1A2CYP2A6MAPT | |
| SCHEMBL1005411 | 0.71 | TSHR (0.47) | HCAR1TSHRCYP1A2CYP2A6MAPT | |
| SCHEMBL1005409 | 0.71 | TSHR (0.47) | HCAR1TSHRCYP1A2CYP2A6MAPT | |
| SCHEMBL29364961 | 0.71 | TSHR (0.52) | HCAR1TSHRCYP1A2CYP2A6MAPT | |
| SCHEMBL397529 | 0.71 | TSHR (0.52) | HCAR1TSHRCYP1A2CYP2A6MAPT | |
| SCHEMBL28883431 | 0.71 | TSHR (0.47) | HCAR1TSHRCYP1A2CYP2A6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10434099-B2 | Methods for treating central nervous system disorders using VDAC inhibitors | The National Institute for Biotechnology in the Negev Ltd. (IL) | 2019-10-08 | — | — | US | disclosed |
| US-20180078548-A1 | Methods for Treating Central Nervous System Disorders Using VDAC Inhibitors | The National Institute for Biotechnology in the Negev Ltd. (IL) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10434099-B2 | Methods for treating central nervous system disorders using VDAC inhibitors | VDAC2, VDAC3, VDAC1 | HCAR1 1320/4885TSHR 3768/4885CYP1A2 1844/4885 |
| US-20180078548-A1 | Methods for Treating Central Nervous System Disorders Using VDAC Inhibitors | VDAC2, VDAC3, VDAC1 | HCAR1 1320/4885TSHR 3768/4885CYP1A2 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.